Debt to Assets Ratio: 28.49%
Is the debt to assets ratio high or low?
The debt to assets ratio of 28.49% is in line with its 3-year average of 30.01%, around the middle of its 3-year range (27.10%–31.70%).
As of Monday, June 29, 2026. 0.54% below its 12-month average of 28.64%.
GEHC Debt to Assets Ratio
Reported quarterly debt to assets ratio; no daily interpolation.
GEHC Average Debt to Assets Ratio Chart
GEHC Current vs Average Debt to Assets Ratio Chart
GEHC Debt to Assets Ratio Metrics
DEBT TO ASSETS RATIO
28.49%
DEBT TO ASSETS RATIO AVG TTM
28.64%
DEBT TO ASSETS RATIO AVG 3Y
29.90%
DEBT TO ASSETS RATIO AVG 5Y
N/A
DEBT TO ASSETS RATIO AVG 10Y
N/A
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-0.54%
CURRENT VS 3Y AVG
-4.73%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
GEHC Competitors' Debt to Assets Ratio
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| GE HealthCare Technologies Inc. (GEHC) | $29.91B | 28.49% | 28.64% | 29.90% | N/A |
| ResMed Inc. (RMD)vs › | $29.05B | 0.10% | N/A | N/A | N/A |
| Zoetis Inc. (ZTS)vs › | $31.88B | 0.61% | N/A | N/A | N/A |
| Biogen Inc. (BIIB)vs › | $31.89B | 0.24% | N/A | N/A | N/A |
| IQVIA Holdings Inc. (IQV)vs › | $31.90B | 0.54% | N/A | N/A | N/A |
| Veeva Systems Inc. (VEEV)vs › | $27.84B | 0.01% | N/A | N/A | N/A |
| Centene Corp. (CNC)vs › | $32.44B | 0.24% | N/A | N/A | N/A |
| DexCom, Inc. (DXCM)vs › | $27.07B | 0.22% | N/A | N/A | N/A |
| Medline Inc. (MDLN)vs › | $32.87B | 0.33% | N/A | N/A | N/A |
| Moderna, Inc. (MRNA)vs › | $26.69B | 0.16% | N/A | N/A | N/A |
Leverage Ratios Comparison
Debt/Assets
28.5%
Debt/Equity
0.96
Current Ratio
1.18
Interest Coverage
6.1x
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
- Debt/Assets: Shows % of assets funded by creditors (bounded 0-100%)
- Debt/Equity: Shows debt relative to shareholder investment (can exceed 100%)
- Both measure leverage but from different perspectives
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt to Assets Ratio Formula & Definition
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Debt to Assets Ratio FAQ
- What is the debt to assets ratio for GE HealthCare Technologies Inc. (GEHC)?
- The debt to assets ratio for GEHC stock is 28.49%.
- Is GE HealthCare Technologies Inc.'s debt to assets ratio high or low?
- The debt to assets ratio of 28.49% is in line with its 3-year average of 30.01%, around the middle of its 3-year range (27.10%–31.70%).
- What is the TTM average debt to assets ratio for GE HealthCare Technologies Inc. (GEHC)?
- The TTM average debt to assets ratio for GEHC stock is 28.64%.
- What is the 3Y average debt to assets ratio for GE HealthCare Technologies Inc. (GEHC)?
- The 3Y average debt to assets ratio for GEHC stock is 29.90%.
GEHC Debt to Assets Ratio History
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-03-31 | 28.49% |
| 2025-12-31 | 27.10% |
| 2025-09-30 | 29.74% |
| 2025-06-30 | 30.54% |
| 2025-03-31 | 27.34% |
| 2024-12-31 | 28.34% |
| 2024-09-30 | 31.70% |
| 2024-06-30 | 30.33% |
| 2024-03-31 | 30.02% |
| 2023-12-31 | 30.39% |
| 2023-09-30 | 31.68% |
| 2023-06-30 | 31.69% |
| 2023-03-31 | 31.37% |
| 2022-12-31 | 31.36% |
About GE HealthCare Technologies Inc.
GE HealthCare Technologies Inc. is a global medical technology company that creates, manufactures, and markets a diverse range of medical devices, services, and integrated digital solutions. These offerings are designed to assist in the diagnosis, treatment, and ongoing monitoring of patients. The company boasts an extensive international presence, serving markets across the United States, Canada, Europe, the Middle East, Africa, China, Taiwan, Mongolia, and Hong Kong, among other regions. Its operations are structured across four primary business divisions: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging division specializes in advanced diagnostic imaging technologies, including systems for molecular imaging, Computed Tomography (CT) scans, Magnetic Resonance (MR) imaging, image-guided therapy, and X-ray, alongside specialized women's health products. The Ultrasound segment delivers a comprehensive suite of ultrasound solutions utilized for the screening, diagnosis, treatment, and monitoring of various diseases. These applications span radiology, primary care, women's health, cardiovascular diagnostics, point-of-care, and portable handheld devices, in addition to products supporting surgical visualization and guidance. The Patient Care Solutions segment is dedicated to providing essential medical devices, consumable products, services, and digital platforms. Its portfolio encompasses patient monitoring, anesthesia delivery and respiratory care, diagnostic cardiology, and maternal-infant care products. The Pharmaceutical Diagnostics segment supplies specialized diagnostic agents to the radiology and nuclear medicine industries. These include contrast media pharmaceuticals, administered to patients prior to scans like CT, angiography, X-ray, and MR, to enhance the visibility of internal tissues and structures. It also offers molecular imaging agents, or radiopharmaceuticals – molecular tracers labeled with radioisotopes – injected into patients for advanced diagnostic imaging applications such as Single-Photon Emission Computed Tomography (SPECT), Positron Emission Tomography (PET), and specific ultrasound procedures. Established in 2022, GE HealthCare Technologies Inc. maintains its corporate headquarters in Chicago, Illinois.
- Sector
- Healthcare
- Industry
- Medical - Healthcare Information Services
- CEO
- Peter J. Arduini